激素原转化酶可将胰高糖素原分子切成不同大小的肽段,包括含肠高血糖素相关胰多肽(GRPP; 氨基酸片段1 - 30)、胰高糖素(氨基酸片段33 - 61)、胃泌酸调节素(OXM;氨基酸片段 33 - 69)的肠高血糖素(氨基酸片段1 - 69)和含胰高糖素样肽1 (GLP-1;氨基酸片段 72-107/108)、胰高糖素样肽2 (GLP-2;氨基...
激素原转化酶可将胰高糖素原分子切成不同大小的肽段,包括含肠高血糖素相关胰多肽(GRPP;氨基酸片段1 - 30)、胰高糖素(氨基酸片段33 - 61)、胃泌酸调节素(OXM;氨基酸片段 33 - 69)的肠高血糖素(氨基酸片段1 - 69)和含...
2.R.A. Ammar,et al, Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome, Inflammopharmacology 30 (3) (2022) 919–934. 3.S. Song, R.Y. Guo, ...
[14] Shigeto, M.; Cha, C.Y.; Rorsman, P.; et al. A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion. J. Mol. Med. 2017, 95, 361–368.
[31] Dai, C., Hang, Y., Shostak, A., Poffenberger, G., Hart, N., Prasad, N., et al. 2017. Agedependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. J Clin Invest 127:3835-3844. ...
自胰高糖素样肽-1(GLP-1)被发现以来,它已然成为一种“多面手”激素——其多种代谢功能被人们发现,远远超出了作为肠促胰素的经典定义。GLP-1的众多有益的靶点作用使其受体激动剂逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药物。时值利拉鲁肽在我国上市10周年,司美格鲁肽新上市之...
[31] Tao, Xin, et al. "Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats." Journal of ovarian research 12.1 (2019): 1-8.[32] Bednarz, Krzysztof, et al. "The role of glp-1 receptor agonists in insulin resistance with concomitant ...
1 GLP-1R激动剂新适应症的拓展和临床实践 慢性、过度的神经炎症是神经退行性疾病的一个主要特征,如阿尔茨海默病(AD)和帕金森病(PD)。然而,神经炎症通路在此类疾病的临床治疗中尚未有效靶向。有趣的是,炎症和神经退行性疾病风险的增加与2型糖尿病(T2DM)和胰岛素抵抗(IR)相关,这表明缓解T2DM病理的治疗可能也能成功...
1)GLP-1 receptor agonistGLP-1受体激动剂 1.The aim of this project is to establish a GLP-1 signaling pathway targeted cell model, for screening the new class of GLP-1 receptor agonists as anti-diabetic candidates.建立以GLP-1信号通路为靶点的药物筛选细胞模型,用于筛选GLP-1受体激动剂类的新型抗...
[5]Laviola L, Leonardini A, Melchiorre M, et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitorcellsby inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology, 2012, 153 : 5770–5781. DOI:10.1210/en...